|Bid||6.89 x 1300|
|Ask||6.95 x 1100|
|Day's Range||6.18 - 7.01|
|52 Week Range||6.18 - 32.00|
|Beta (5Y Monthly)||1.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.17|
Subscribe to Yahoo Finance Plus to view Fair Value for ADCT
LAUSANNE, Switzerland, May 12, 2022--ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation at the European Hematology Association 2022 Hybrid Congress (EHA2022), which will be held virtually and in Vienna, Austria from June 9-12, 2022.
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LAUSANNE, Switzerland, May 09, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today reported financial results for the first quarter ended March 31, 2022 and provided business updates.